Search Results for: 19

— The University of Texas at Austin Receives Grant from the Bill & Melinda Gates Foundation — ROCKVILLE, Md. and AUSTIN, Texas, Oct. 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, and its Pertussis academic collaborator, The University of […]

— Company’s SYN-010 Program to Reduce the Impact of Methane Gas in the Gut Currently in Phase 2 Clinical Trials — ROCKVILLE, Md., Oct. 20, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that experimental results supporting the proposed

— Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST — ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September

— Trial to Evaluate the Ability of SYN-010 to Sustain the Reduction of Methane Production in the Gut for Patients who have Completed First Phase 2 Clinical Trial of SYN-010 — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., Oct. 8, 2015 /PRNewswire/

— Manufacturing Executive Served Most Recently in Leadership Positions at Merck &Co. — — Appointment Reflects Company’s Focus on Preparing for Late-Stage Clinical Trials — ROCKVILLE, Md., Oct. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that Raymond

— Study to Evaluate SYN-004’s Ability to Prevent C. difficile Infection and Antibiotic-Associated Diarrhea — — Phase 2b Trial Expected to Enroll Approximately 370 Patients at up to 75 Global Clinical Sites — ROCKVILLE, Md., Sept. 28, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect

— Late-Breaker Oral Presentation at ICAAC/ICC 2015 Highlights Data from Novel Gut Microbiome Program — ROCKVILLE, Md., Sept. 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, presented data from its novel SYN-004 program that demonstrated SYN-004 protected the

ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Achieved Planned Milestones for Company’s Lead Microbiome Drug Candidates Enhanced Senior Management Team to Maximize Strategic Opportunities Strengthens Balance Sheet to Support Microbiome Clinical Trials Conference Call Today, August 10, 2015, at 8:30 a.m. EDT Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to

Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics™ Platform without Adverse Impact on Gut Microbiome GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Conference Call Scheduled for Monday, August 10, 2015 at 8:30 a.m. EDT — ROCKVILLE, Md., July 29, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and six months ended June